The Secretary for Health, Professor Lo Chung-mau, met with the Chairman of the Changchun Committee of the Chinese People's Political Consultative Conference (CPPCC), Mr Gao Zhiguo, today (June 16) to have in-depth exchanges on the development of biomedicine and Chinese medicine (CM) in the two places.

     Professor Lo said, "Biomedicine development and medical innovation are not only directly related to people's life and health, but also important national policies representing immense new quality productive forces. The Resolution of the Communist Party of China (CPC) Central Committee on Further Deepening Reform Comprehensively to Advance Chinese Modernization adopted by the Third Plenary Session of the 20th CPC Central Committee pointed out the need to deepen the reform of medical and healthcare system and emphasised the support to the development mechanisms for innovative drugs and medical devices. In addition, the Development Plan for Shenzhen Park of Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone promulgated by the State Council also put forward the co-ordinated development of the Hong Kong Special Administrative Region (HKSAR) and Shenzhen under 'one zone, two parks' to promote the innovative application of advanced biomedicine technologies with concerted effort."

     "The HKSAR Government is determined to fully utilise the institutional advantages of 'one country, two systems' of the HKSAR and our professional strengths in the healthcare sector to develop Hong Kong into an international health and medical innovation hub, thereby enabling the innovative medical technologies to go global and attract foreign investment, and promoting new quality productive forces in biomedicine."

     The Chief Executive put forward the initiative of developing Hong Kong into an international health and medical innovation hub in his 2023 and 2024 Policy Address. The HKSAR Government will expedite the reform of the approval mechanism for drugs and medical devices and enhance the translation of innovative biomedical research results into clinical applications, such as jointly establishing the Greater Bay Area (GBA) Clinical Trial Collaboration Platform in concerted efforts by the GBA International Clinical Trial Institute in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone and the GBA International Clinical Trials Center in the Shenzhen Park to integrate resources and technologies to provide one-stop clinical trial support for medical research institutions; establishing a Real-World Study and Application Centre to open up the extensive and standardised local medical databases to support clinical diagnosis and treatment, new drug development, and public health research, and integrate real-world data generated through the special measure of using Hong Kong-registered drugs and medical devices used in Hong Kong public hospitals in the GBA to accelerate approval for registration of new drugs in Hong Kong, the Mainland, and overseas; preparing for the establishment of the Hong Kong Centre for Medical Products Regulation (CMPR) to progress towards the "primary evaluation" approach; and taking forward preparatory work for legislating for the statutory regulation of medical devices to dovetail with the timetable for the establishment of the CMPR.

     Regarding CM, the HKSAR Government is committed to developing Hong Kong into a bridgehead for the internationalisation of CM, and encourages co-operations between schools and research institutions of the two places in various areas such as CM education and research. Hong Kong's first CM hospital will commence services in phases starting from the end of this year, which will serve as a key platform for promoting clinical scientific research collaboration in proprietary Chinese medicines development, synergising with the GBA Clinical Trial Collaboration Platform to facilitate the commencement of internationally recognised multicentre clinical trials, thereby further accelerating the translation of CM research findings.

     Representatives of the Health Bureau, the Department of Health and the Hospital Authority also attended the meeting.

Ends/Monday, June 16, 2025
Issued at HKT 20:50

NNNN